Atrial fibrillation in congestive heart failure: current management.
Atrial fibrillation (AF) and congestive heart failure are common conditions and each predisposes to the development of the other. Basic research using animal models of the two conditions continues to yield insights that may improve therapies. The role of medical therapies aimed at the underlying structural changes in AF continues to be a subject of ongoing studies. Cardiac resynchronization therapy is effective in appropriately selected patients with both sinus rhythm and AF. Catheter ablation is emerging as a potential alternative to antiarrhythmic drug therapy, but large randomized trials will be needed to assess its role.
Boyle
Noel G
NG
UCLA Cardiac Arrhythmia Center, Division of Cardiology, Department of Medicine, BH 407 CHS, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679, USA. nboyle@mednet.ucla.edu
Shivkumar
Kalyanam
K
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods*; D004554:Electric Countershock / Q000379:methods*; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006339:Heart Rate / Q000502:physiology; D006801:Humans; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants